Does elevated TMAO reflect gut microbial conversion of dietary precursors and liver oxidation?

Trimethylamine N-oxide (TMAO) is a key gut-microbiome-derived metabolite that links dietary intake with host vascular biology, serving as an important marker of cardiometabolic risk.

Metaorganismal biosynthesis pathway

• Microbial fermentation: Dietary precursors, including choline, L-carnitine, and lecithin, undergo fermentation by gut microbiota expressing specific enzyme complexes, such as anaerobic choline TMA-lyase (CutC/D) and carnitine monooxygenase (CntA/B), to produce gaseous trimethylamine (TMA).
• Hepatic oxidation: Once synthesized, TMA is absorbed into the portal circulation and transported to the liver, where host hepatic flavin-containing monooxygenase 3 (FMO3) catalyzes its oxidation into systemic TMAO.

Cardiometabolic risk and clinical evidence

• Mortality and vascular risk: High circulating TMAO is strongly linked to cardiovascular disease (CVD) and major adverse cardiovascular events (MACE). In the Cardiovascular Health Study of older adults, individuals in the highest quintile of TMAO had an approximately 30% higher relative risk of all-cause mortality compared to those in the lowest quintile.
• Renal modulation: Because TMAO is cleared by the kidneys, reduced renal function (eGFR < 60 mL/min/1.73 m²) impairs clearance, elevating circulating levels and significantly amplifying associated cardiovascular risks.
• Clinical thresholds: Although concentrations between 4 and 6 µM/L are commonly identified as risk thresholds in cohort studies, universally standardized clinical screening cutoffs have not yet been established.

Bottom line

• Elevated circulating TMAO is a direct product of gut microbial metabolism of dietary nutrients followed by hepatic FMO3 oxidation, and is robustly associated with increased cardiometabolic and mortality risks, particularly in older populations and individuals with compromised kidney function.